Novo Nordisk A/S Sponsored ADR (NVO)
NYSE
Real-time Data
01:30 PM
Day's Range
46.3452 wk Range
35.12Overview - NVO - Novo Nordisk A/S Sponsored ADR
Key Statistics
Valuation
Enterprise Value
47.18B
P/E (Trailing)
‪11.40‬
P/E (Forward)
‪13.59‬
PEG Ratio
‪-0.55‬
Price / Sales (TTM)
‪0.62‬
Price / Book
‪6.66‬
EV / EBITDA
‪1.74‬
Profitability
Gross Margin
‪78.21%‬
Profit Margin
‪35.34%‬
Operating Margin
‪42.54%‬
Return on Assets
‪18.72%‬
Return on Equity
‪59.81%‬
Ownership
Shares Outstanding
4.42B
Float
3.17B
Short % of Shares Outstanding
‪0.93%‬
Held by Insiders
‪0.0030%‬
Held by Institutions
‪9.90%‬
Price stats
Beta
‪0.34‬
50-Day Avg
‪47.58‬
200-Day Avg
‪46.42‬
Dividends
Payout Ratio
‪44.46%‬
Frequency
Semi-Annual
Analyst Consensus
14 analysts
Average price target
‪$ 47.49‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - NVO - Novo Nordisk A/S Sponsored ADR
Peers - NVO - Novo Nordisk A/S Sponsored ADR
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on NYSE.
- NVONYSENovo Nordisk A/S206.68BMarket Cap-20.54%52-week change11.59P/E (Trailing)‪35.34%‬Profit Margin
- LLYNYSEEli Lilly and Company1.11TMarket Cap+44.61%52-week change42.21P/E (Trailing)‪33.52%‬Profit Margin
- JNJNYSEJohnson & Johnson651.25BMarket Cap+33.98%52-week change31.35P/E (Trailing)‪21.48%‬Profit Margin
- ABBVNYSEAbbVie Inc.468.21BMarket Cap+21.67%52-week change75.06P/E (Trailing)‪9.80%‬Profit Margin
- MRKNYSEMerck & Co., Inc.376.36BMarket Cap+44.08%52-week change122.04P/E (Trailing)‪4.76%‬Profit Margin
- NVSNYSENovartis AG Sponsored ADR301.94BMarket Cap+21.29%52-week change24.00P/E (Trailing)‪22.50%‬Profit Margin
- SANNYSEBanco Santander S.A. Sponsored ADR212.65BMarket Cap+34.20%52-week change14.17P/E (Trailing)‪33.46%‬Profit Margin
Profile Summary - NVO - Novo Nordisk A/S Sponsored ADR
About
Novo Nordisk is a leading global pharmaceutical company headquartered in Denmark that specializes in developing and manufacturing medicines to treat serious chronic diseases. The company focuses on four primary therapeutic areas: diabetes, obesity, cardiovascular disease, and rare diseases including hemophilia and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
